JP2023549537A - 多重特異性抗体およびその使用方法 - Google Patents

多重特異性抗体およびその使用方法 Download PDF

Info

Publication number
JP2023549537A
JP2023549537A JP2023528957A JP2023528957A JP2023549537A JP 2023549537 A JP2023549537 A JP 2023549537A JP 2023528957 A JP2023528957 A JP 2023528957A JP 2023528957 A JP2023528957 A JP 2023528957A JP 2023549537 A JP2023549537 A JP 2023549537A
Authority
JP
Japan
Prior art keywords
sequence
seq
polypeptide
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549537A5 (enExample
Inventor
モハド サイフ ザマン
ユエ リュウ
Original Assignee
エイビー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイビー セラピューティクス インコーポレイテッド filed Critical エイビー セラピューティクス インコーポレイテッド
Publication of JP2023549537A publication Critical patent/JP2023549537A/ja
Publication of JP2023549537A5 publication Critical patent/JP2023549537A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023528957A 2020-11-16 2021-11-16 多重特異性抗体およびその使用方法 Pending JP2023549537A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063114479P 2020-11-16 2020-11-16
US63/114,479 2020-11-16
US202163237526P 2021-08-26 2021-08-26
US63/237,526 2021-08-26
PCT/US2021/059444 WO2022104236A2 (en) 2020-11-16 2021-11-16 Multispecific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023549537A true JP2023549537A (ja) 2023-11-27
JP2023549537A5 JP2023549537A5 (enExample) 2024-11-20

Family

ID=81601772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528957A Pending JP2023549537A (ja) 2020-11-16 2021-11-16 多重特異性抗体およびその使用方法

Country Status (4)

Country Link
US (1) US20230399408A1 (enExample)
EP (1) EP4243938A4 (enExample)
JP (1) JP2023549537A (enExample)
WO (1) WO2022104236A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525275A (ja) 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
CN119948063A (zh) * 2022-06-23 2025-05-06 信达生物制药(苏州)有限公司 结合egfr和b7-h3的双特异性抗体
CA3256857A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. EGFR/MET ANTIBODIES AND THEIR USES
JP2026513451A (ja) * 2023-04-24 2026-04-27 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 ｃ－Ｍｅｔを標的とする多重特異性抗体
AU2024315062A1 (en) * 2023-07-28 2026-03-12 Tigatx, Inc. Engineered iga antibodies and methods of use
CN121969654A (zh) * 2023-08-02 2026-05-01 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
WO2025042806A2 (en) * 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
CN120271706A (zh) 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
WO2026021476A1 (en) * 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates
WO2026145588A1 (en) * 2024-12-31 2026-07-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of egfr/c-met bispecific binding protein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520129A (ja) * 2011-06-23 2014-08-21 アブリンクス エン．ヴェー． 血清アルブミンに結合するタンパク質
JP2016504291A (ja) * 2012-11-21 2016-02-12 ヤンセン バイオテツク，インコーポレーテツド Ｅｇｆｒ及びｃ−ｍｅｔフィブロネクチンｉｉｉ型ドメイン結合分子
JP2016505537A (ja) * 2012-11-21 2016-02-25 ヤンセン バイオテツク，インコーポレーテツド 二重特異性ＥＧＦＲ／ｃ−Ｍｅｔ抗体
WO2019134710A1 (en) * 2018-01-08 2019-07-11 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2012042026A1 (en) * 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
RS66708B9 (sr) * 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
WO2020172528A1 (en) * 2019-02-22 2020-08-27 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
JP2022525275A (ja) * 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
MY208668A (en) * 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520129A (ja) * 2011-06-23 2014-08-21 アブリンクス エン．ヴェー． 血清アルブミンに結合するタンパク質
JP2016504291A (ja) * 2012-11-21 2016-02-12 ヤンセン バイオテツク，インコーポレーテツド Ｅｇｆｒ及びｃ−ｍｅｔフィブロネクチンｉｉｉ型ドメイン結合分子
JP2016505537A (ja) * 2012-11-21 2016-02-25 ヤンセン バイオテツク，インコーポレーテツド 二重特異性ＥＧＦＲ／ｃ−Ｍｅｔ抗体
WO2019134710A1 (en) * 2018-01-08 2019-07-11 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP2021509896A (ja) * 2018-01-08 2021-04-08 ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 多重特異性抗原結合タンパク質及びその使用方法

Also Published As

Publication number Publication date
EP4243938A4 (en) 2025-03-05
WO2022104236A3 (en) 2023-03-09
US20230399408A1 (en) 2023-12-14
WO2022104236A2 (en) 2022-05-19
EP4243938A2 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
US20230399408A1 (en) Multispecific antibodies and uses thereof
US10934365B2 (en) Anti-OX40 antibodies and uses thereof
US20240109963A1 (en) Multispecific antibodies and uses thereof
CN116940597A (zh) 多特异性抗体及其用途
KR20250028357A (ko) 항-egfr/met 항체 및 이의 용도
US20240002539A1 (en) Multispecific antibodies and uses thereof
US20250368742A1 (en) Anti-mica/b antibodies and uses thereof
CN119176876A (zh) 抗b7-h4抗体及其应用
KR20250023399A (ko) 항-siglec15 항체 및 이의 용도
JP2024547122A (ja) 抗ｔｎｆｒ２抗体及びその使用
WO2025180385A1 (en) Anti-egfr/cd70 antibodies and uses thereof
WO2024208244A1 (en) Anti-igf1r antibodies and uses thereof
EP4543488A2 (en) Multispecific antibodies and uses thereof
WO2022037672A1 (en) Anti-cd47 antibodies and uses thereof
KR20250005109A (ko) 항-cd40 항체 및 이의 용도
RU2783314C2 (ru) Антитела против ox40 и их применения
JP2026508209A (ja) 抗ｉｌ２ｒａ抗体及びその使用
HK40039579A (en) Anti-ox40 antibodies and uses thereof
HK40039579B (en) Anti-ox40 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260716

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260806